SpicTrans
Financiado
Species-specific aspects in eukaryotic mRNA translation modulation and their imp...
Species-specific aspects in eukaryotic mRNA translation modulation and their implications in diseases
mRNA translation is a universally conserved process consisting on translating the genetic code into proteins, the primary building blocks of all living organisms. Translation is mainly operated by the ribosome, a hybrid molecule m...
mRNA translation is a universally conserved process consisting on translating the genetic code into proteins, the primary building blocks of all living organisms. Translation is mainly operated by the ribosome, a hybrid molecule made of RNAs and proteins. In most eukaryotes, at least two types of mRNA translation coexist in nearly all cells. Indeed, although the quasi totality of the proteins is translated in the cytosol by the cytosolic ribosome, a small yet essential fraction of mRNA translation can take place in the mitochondria, the cell’s power plant. While mitochondrial translation process has proven to be substantially species-specific, numerous species-specific structural and regulatory differences also exist in the cytosolic translation process in spite of their relative conservation among eukaryotic species and are yet to be elucidated. We will use various structural and molecular biology methods to investigate, from a disease-related perspective, several species-specific aspects of mRNA translation modulation in mammals and in pathogenic parasites from the family of kinetoplastids. Namely, 1- we will investigate the molecular roles of several kinetoplastid-specific proteins involved in translation and evaluate their validity as pharmacophores. 2- We will study mitochondrial translation in kinetoplastids and focus on its variable regulation in different forms of the parasites during their life-cycle (blood vs. insect stages). 3- We will study cytosolic mRNA scanning for the start-codon during translation initiation to i) understand its molecular basis in different types of mRNAs (native and modified mRNAs, natural or artificial), ii) and investigate its alteration in colorectal cancer caused by the absence of a ribosomal RNA modification. Results will advance our knowledge of species-specific mRNA translation and open new perspectives for developing treatments against various human diseases and infections (anti-parasites, cancer therapy, mRNA vaccines).
ver más
Duración del proyecto: 64 meses
Fecha Inicio: 2023-02-23
Fecha Fin: 2028-06-30
Fecha Fin: 2028-06-30
Línea de financiación: concedida
El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2023-02-23
Línea de financiación objetivo
El proyecto se financió a través de la siguiente ayuda:
ERC-2022-COG:
ERC CONSOLIDATOR GRANTS
Cerrada
hace 2 años
Presupuesto
El presupuesto total del proyecto asciende a
2M€
Líder del proyecto
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHER...
No se ha especificado una descripción o un objeto social para esta compañía.
Perfil tecnológico
TRL
4-5
Perfil tecnológico
TRL
4-5